Pfizer's CDK2-selective inhibitor in Phase 1/2 development for HR+/HER2- metastatic breast cancer.
Tegtociclib (PF-07104091) is an investigational CDK2-selective inhibitor under clinical investigation by Pfizer. Preclinical models show it selectively binds to and inhibits CDK2 activity, which may lead to cell cycle arrest through reduced phosphorylation of retinoblastoma protein, and it is being studied in Phase 1/2a monotherapy and combination studies in HR+/HER2- metastatic breast cancer (NCT04553133), where resistance to CDK4/6 inhibition is a treatment challenge.
CDK2 is a cell-cycle regulator activated by cyclins E and A, and selective CDK2 inhibition is being studied as a therapeutic approach for tumor types driven by CDK2 activity. Tegtociclib is investigational; its safety and efficacy have not been established.
Adds products that compete with one of Tegtociclib (PF-07104091)’s direct competitors but not with Tegtociclib (PF-07104091) itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | Tegtociclib (PF-07104091) | ARTS-021 / AVZO-021 (CDK2 selective inhibitor) | Incb123667 | INX-315 | |
|---|---|---|---|---|---|
| Linked Through | — | Direct competitor | ARTS-021 / AVZO-021 (CDK2 selective inhibitor) | ARTS-021 / AVZO-021 (CDK2 selective inhibitor) | |
| Provider | |  |  |  | |
| Founded | 1849 | 2020 | 1991 | 2020 | |
| Sells To | Non-Profit | Enterprise | Enterprise | Enterprise | |
| Pricing Model | Recurring | Recurring, Software | Recurring, Software | Recurring | |
| Ownership | Private | Private | Public | Private, Venture-backed |
Provider
Founded 1849
Sells To Non-Profit
Pricing Model Recurring
Ownership Private
Provider
Founded 2020
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Private
Linked Through ARTS-021 / AVZO-021 (CDK2 selective inhibitor)
Provider
Founded 1991
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Linked Through ARTS-021 / AVZO-021 (CDK2 selective inhibitor)
Provider
Founded 2020
Sells To Enterprise
Pricing Model Recurring
Ownership Private, Venture-backed
Selective CDK4 inhibitor for HR+ breast cancer partnered with Avenzo.
Incyte's selective oral CDK2 inhibitor in Phase 1 development for advanced solid tumors.
Incyclix Bio's potent and selective CDK2 inhibitor in first-in-human Phase 1/2 development.
Selective CDK4 inhibitor for HR+ breast cancer partnered with Avenzo.
Incyte's selective oral CDK2 inhibitor in Phase 1 development for advanced solid tumors.
Incyclix Bio's potent and selective CDK2 inhibitor in first-in-human Phase 1/2 development.